IgG4 serum levels in Graves’ orbitopathy

Comi S.;Lanzolla G.;Cosentino G.;Maglionico M. N.;Posarelli C.;Menconi F.;Santini F.;Elisei R.;Marino M.

2024-01-01

---

Abstract

Objective: IgG4-related disease (IgG4-RD) can involve many organs, including thyroid and orbital tissues. A link between IgG4, Graves’ disease (GD) and Graves’ orbitopathy (GO) has been proposed, but results are conflicting. Here we investigated the possible association between IgG4 and GO. Methods: Retrospective investigation in 297 patients with Graves’ disease (GD), 152 with GO. Primary outcome: prevalence of IgG4 ≥ 135 mg/dL (cut-off for IgG4-RD). Secondary objectives: (1) serum IgG4 concentrations; (2) IgG4/IgG ratio; (3) prevalence of IgG4/IgG ratio ≥ 8.0%; (4) relationship between IgG4 and eye features; (5) relationship between IgG4 and anti-TSH receptor antibodies (TRAbs). Results: Because GO patients had lower FT3 concentrations, we evaluated the main objectives in the second and third FT3 quartiles subpopulation, in which there were no relevant differences between patients with (n = 81) or without GO (n = 67) for baseline parameters. Within this population, the prevalence of IgG4 levels ≥ 135 mg/dL did not differ between patients without and with GO (17.9% vs 17.3%). No difference was observed concerning IgG4 concentrations, prevalence of IgG4/IgG ≥ 8.0%, and IgG4/IgG ratio. There was no relationship between IgG4 and eye features and no correlation between IgG4 levels and TRAb was found. Conclusions: Our results suggest that, within GD, there is no relationship between serum IgG4 and GO.